ASAM COVID-19 Resources
- Ensuring Access to Care in Opioid Treatment Programs
- Addiction Treatment in Hospital Settings During the COVID-19 Crisis
- Treating Pregnant People with OUD
- Access to Buprenorphine in Office-Based Settings
- Infection Control and Mitigation Strategies in Residential Treatment Facilities
- Infection Mitigation in Outpatient Settings
COVID-19 Resources from ASAM
COVID-19 Resources from the NAM’s Action Collaborative on Countering the U.S. Opioid Epidemic
Treating Addiction Across the Care Continuum During COVID-19: Challenges and Promising Practices
When: Thursday, May 22, 2020 | 2:30 to 4:00 p.m. ET
Access Webinar #2 Presentation Slides
This 90-minute webinar will review current approaches, challenges, and promising practices for addiction treatment across the continuum of care in the context of COVID-19. The session will include introductions from Elizabeth Finkelman, Director of the NAM’s Action Collaborative on Countering the U.S. Opioid Epidemic, and Dr. Kelly Clark, Immediate Past President of ASAM, followed by presentations from three panelists and moderated Q&A with the webinar audience.
2:30 p.m. ET | Welcome
- Elizabeth Finkelman, MPP – Director, Action Collaborative on Countering the U.S. Opioid Epidemic, National Academy of Medicine
- Kelly Clark, MD, MBA, DFAPA, DFASAM – Immediate Past President, American Society for Addiction Medicine
2:40 p.m. ET | Panel Presentations
Moderator: Kelly Clark
- Margaret Jarvis, MD, DFASAM, Chief of Addiction Medicine for the Geisinger Health
- Melissa Weimer, DO, FASAM, Assistant Professor, and Medical Director of the Yale Addiction Medicine Consult Service
- Vincent Nelson, MD, MBA, FASA, Vice President, Medical Affairs and Interim Chief Medical Officer, Blue Cross Blue Shield Association
3:25 p.m. ET | Moderated Discussion and Audience Q&A
3:55 p.m. ET | Closing Remarks
4 p.m. ET | Adjourn
AMA Credit Designation Statement:
The American Society of Addiction Medicine designates this internet live course for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The American Society of Addiction Medicine and National Academy of Medicine. The American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical education for physicians.
NAADAC, the Association for Addiction Professionals:
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for 1.5 Continuing Education (CE) credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
Elizabeth Finkelman, MPP, Senior Program Officer, National Academy of Medicine
Elizabeth Finkelman is a Senior Program Officer in the Office of the President at the National Academy of Medicine. In her role, she directs NAM special projects and initiatives, including the Action Collaborative on Countering the U.S. Opioid Epidemic, the Healthy Longevity Global Competition, and previously, the Vital Directions for Health and Health Care initiative. Prior to joining the NAM in 2015, Elizabeth spent several years working in program administration and research within the Division on Earth and Life Studies at the National Academies. She completed her undergraduate degree at McGill University, double majoring in cell and molecular biology and political science. Elizabeth has a Master of Public Policy degree from the George Washington University with a concentration in health policy.
Kelly J. Clark, MD, MBA, Immediate Past President, American Society of Addiction Medicine
Kelly J. Clark, MD, MBA, DFAPA, DFASAM currently serves as President of the American Society of Addiction Medicine, the largest group of physicians specializing in addiction in the country with over 5,500 addiction physician specialists and allied health professionals. In addition to direct clinical practice, Kelly has focused her career on issues of addictive disease, evidence informed and quality behavioral health care, and payment reform. Board certified in both psychiatry and addiction medicine, Clark founded Addiction Crisis Solutions to provide both consulting and education of all stakeholder groups in the service of transforming addiction care into evidence-based, cost-effective practice. Dr. Clark’s previous work includes roles as CMO of CleanSlate Centers, CMO of Behavioral Health Group, medical director at CVS Caremark focusing on overutilization of controlled substances, and the behavioral health medical director lead for the in-sourcing of that benefit at Capitol District Physician’s Health Plan. A frequent speaker and addiction policy contributor, she has provided expertise about the opioid crisis to the US Presidential Opioid Commission, FDA, SAMHSA, the Office of Comptroller General; the Pew Trusts, National Safety Council, and National Business Group on Health; as well as numerous provider and payer organizations. Clark earned her MBA from the Fuqua School of Business at Duke University with additional Certification in Health Sector Management, her Doctor of Medicine degree from the University of Wisconsin, and a BA from Coe College.
Margaret Jarvis, MD, DFASAM, Chief of Addiction Medicine for the Geisinger Health
Margaret Jarvis, MD, DFASAM, completed medical school, a psychiatry residency, and a fellowship in substance abuse medicine at the Medical College of Virginia (now Virginia Commonwealth University). She has worked for the Geisinger Health System in Pennsylvania since 1999, first as the medical director of Marworth, the ASAM level 3.7 rehabilitation center, and more recently as the chief of the addiction medicine service line. She has done much work for ASAM over her career, serving as an officer of the board, and chairing councils and committees. She has also been on the examination writing committee, first for ASAM, then for ABAM, and most recently for ABPM.
Melissa Weimer, DO, FASAM, Assistant Professor, and Medical Director of the Yale Addiction Medicine Consult Service
Melissa Weimer, DO, FASAM, is board-certified in Internal Medicine and Addiction Medicine and an Assistant Professor of Medicine at Yale University School of Medicine. At Yale, she also serves as the Medical Director of the Yale Addiction Medicine Consult Service and Associate Program Director of the Addiction Medicine Fellowship Program. Dr. Weimer has a clinical and research focus on expanding access to treatment for patients with substance use disorders, particularly in the hospital setting.
Vincent Nelson, MD, MBA, FASA, Vice President, Medical Affairs and Interim Chief Medical Officer, Blue Cross Blue Shield Association.
Vincent Nelson, M.D., is Vice President of Medical Affairs in the Office of Clinical Affairs for the Blue Cross Blue Shield Association, a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield (BCBS) companies. The BCBS System is the nation’s largest health insurer covering one in three Americans. Dr. Nelson provides clinical leadership across multiples disciplines, including quality management, provider recognition, medical policy, innovations of service delivery, and strategic market opportunities.
This webinar is the second in a series called “Supporting People With Addiction During COVID-19”, hosted by the National Academy of Medicine and the American Society for Addiction Medicine. Join our U.S. Opioid Epidemic listserv to be notified of new resources and upcoming events.
Questions? Trouble accessing the webinar? Please contact firstname.lastname@example.org